Day 1 :
Chairman, President/CTO in Medical device companies: X-Cardio, Tokyo, GoldTech Sino, HK, Concardio, Inc., Cleveland and HeartBeat Technologies, Israel, and JV with LifeQ, SA, US, NL
Time : 09:55
Ehud Baron MD D.Sc, Ex-prof. and researcher in Technion – Israel Inst. Of Technology, Aalborg University, UC Berkeley and Stanford University. Serial entrepreneur that serves as Chairman, President/CTO in Medical device companies: X-Cardio Corp. KK, Tokyo, GoldTech Sino, HK, Concardio, Inc., Cleveland and HeartBeat Technologies, Ltd., Israel, and JV with LifeQ, SA, US, NL.
The Problem: In order to appreciate the meaning of Hypertension beyond BP numeric value, we can employ 24H unobtrusive monitoring of cardiovascular health to assess progress or deterioration, and produce 24H BP graphs and Personal Health Maps (PHM)
Methodology: We suggest PHM for each patient to provide at a glance the position of the patient on the Health Space at any given time. It is based on Fuzzy sets, where each patient get different level of membership in different pathological and healthy conditions. The PHM shows the patient’s Pulse Shape trace during the night and condition can be assessed in one glance. In one study in Calcutta hospital, 30 hypertensive and diabetic patients were monitored at home 24H both with ABPM recording their BP every 15 min and continuous PPG that was used to predicted BP and Cardiac Output continuously. In a second clinical trial we compared our Hemodynamics prediction to Continuous Hemodynamics CNAP device, during Hemodialysis in Fresenius Kidney Center, in St. Louis hospital. Using 2-4 light wavelengths allowed us also to interrogate the capillary bed at different penetration levels to estimate features related to the microcirculation.
Findings: We did Fuzzy clustering by an algorithm we developed to cluster the pulse shapes in the feature space. We discovered that different health conditions fell into different clusters.
Conclusions & Significance: The finding that different health condition can be defined by the BP pulse shape clustering, generates a continuous Health space. Cluster centroids that represent various pulse shape belong to different health conditions. This provides a powerful tool to see patients progress or deterioration in a quantitative way that also indicates the way for more effective interventions. It is only the very beginning but first finding look quite promising. This can solve the problem of cardiology at night time, or how to detect deterioration in early stage in an unobtrusive and automatic way during night watch.
CEO, Tarilian Laser Technologies and ViCardio & Senior Clinical Fellow, The Barts Heart Centre, London
Keynote: A Dynamic New World Order for Digital Blood Pressure Measurement: Introduction to Tarilian Laser Technologies
Time : 11:05 AM
Dr Sandeep Shah is a leading pioneer in the Medtech Industry and a Medical Doctor, an international Medical Technology Development Expert with sector expertise in technology transfer, regulation, clinical research, market adoption and business development. He is an expert on blood pressure measurement and haemodynamics. Sandeep is Co-Founder and CEO of Tarilian Laser Technologies and ViCardio® Ltd, which has developed an award-winning patented powerful cuffless non-invasive solution to blood pressure measurement and haemodynamics.
Tarilian Laser Technologies (TLT) is an innovative Medtech Company based in Welwyn Garden City, Hertfordshire & Leeds and also Minneapolis, Minnesota, USA. Our main clinical centre is The Barts Heart Centre in London, Europe’s largest cardiovascular research centre. At TLT, we have developed a novel optical platform technology based on our internal proprietary patented opto-electronic micro-sensor for full haemodynamic profiling including our ability to generate beat to beat blood pressure, compliance data, cardiac output and regional blood flow and blood pressure. A unique aspect of the TLT Sapphire sensor is that no energy enters the body at all – hence, it is truly non-invasive and does not require any compression/cuff and nor any calibration. The sensor is simply applied onto the body and it works instantly delivering continuous beat to beat haemodynamic data. The technology has already won many international awards and TLT has over 47 issued patents. TLT is finalizing its manufacturing translation programme for market launch. The TLT technology is set to revolutionize blood pressure measurement and cardiology, including in the community, hospital ward and OPD and critical care; and also, the emerging consumer wearable markets. An additional interest is the ability of our technology to measure regional/localized blood pressure and flow: including central retinal, renal arterial, maternal and fetal and placental blood pressure and flow. TLT has also commenced major programme of research on blood pressure variability and novel carotid applications especially in relation to the carotid body and sinus. The author will present the data from the pivotal study comparing the TLT technology performance to that of the intra-arterial line (IABP) at The Barts Heart Centre ICU.
CTO, Co-Founder, Tarilian Laser Technologies( TLT ) and Vicardio ® Ltd.
Keynote: The future horizons for development of digital products for the cardiovascular sector and the impact of machine learning
Time : 11:50 AM
The author will describe the exciting new modern world of digital Medtech development – the future significance of digital products and their disruption of modern day cardiovascular medical and surgical management through novel sensing platforms. She will expand on future horizons in biometric sensing in cardiology– the opportunities, challenges and likely impacts on clinical care pathways. The author will also describe the journey of development of Tarilian Laser Technologies (TLT) – which is an innovative Medtech Company based in Welwyn Garden City, Hertfordshire and Leeds and also Minneapolis, Minnesota, USA; with its main clinical center being at The Barts Heart Centre in London, Europe’s largest cardiovascular research center. TLT have developed a novel optical platform technology based on its internal proprietary patented opto-electronic micro-sensor for full hemodynamic profiling including our ability to generate beat to beat blood pressure, compliance data, cardiac output and regional blood flow and blood pressure. She will also describe the modern world of rapid product development and prototyping, how to engage doctors, nurses and patients in product design and development, and how the industry is going through a new revolution through the impact of Artificial Intelligence Systems.